Good Price High Quality Pharmaceutical Raw Material Peptide Lypressin Acetate CAS 50-57-7

• CAS No.: 50-57-7
• Formula: C48h69n13o14s2
• EINECS: 200-050-5
• Environmental Protection: Yes
• Certification: ISO
• Color: White
• Model NO.: powder
• Classification: Peptide
• Function: Keeping Health and Promoting Growth
• Appearance: Powder
• Transport Package: 10g/Al Bag
• Specification: 99%
• Trademark: Huadi
• Origin: China
• Production Capacity: 10000g/Month

Product Description

Lyspressin is used in situations such as persistent low blood pressure and very low blood pressure due to certain conditions. Lyspressin works by raising blood pressure, increasing blood vessel capacity, and vascular resistance, while reducing the permeability of dialysate fluid.
The main application areas of lyspressin are as follows:
Treatment of low blood pressure and associated shock in emergency situations: Lyspressin is used in severe low blood pressure and shock situations to increase blood pressure and blood flow.
Treatment and prevention of growth and developmental disorders related to chills and congenital diabetes: Lyspressin is used to treat or prevent growth and developmental disorders over time.
Huadi Group is a national high-tech enterprise. It is invested and established by a group of professionals who are specialized in the R&D of the biopharmaceutical field and have rich experience in production management and operation. It is a group company that invests in the production of diversified industries such as pharmaceuticals, medical devices, food, health products, cosmetics, and biological agriculture products.

Huadi Group has a total of 8 subsidiaries: Zhejiang Huadi Pharmaceutical Group Co., Ltd., Hangzhou Huajin Pharmaceutical Co., Ltd., Zhejiang Huajun Pharmaceutical Co., Ltd., Zhejiang Huadi Pharmaceutical Group Pharmaceutical Development Co., Ltd., Hangzhou Huadi Health Technology Co., Ltd., Leizhou Huadi Biotechnology Co., Ltd., Hainan Huadi Pharmaceutical Co., Ltd., Hunan Huadi Biotechnology Co., Ltd.

Huadi Group is the vice president unit of the China Biochemical Pharmaceutical Industry Association and the vice president unit of the Zhejiang Health Industry Research Association. Its controlling subsidiary, Zhejiang Huadi Pharmaceutical Group, is the drafting unit of the GMP appendix for biochemical drugs of the National Good Manufacturing Practice for Drugs. The group has two provincial-level R&D centers, the Chief Scientist is a senior scientist and overseas returnee PhD from a fortune 500 company in the United States. The company has long hired domestic and foreign experts and scholars as technical consultants, with strong technological innovation capabilities. With nearly 30 years of R&D and industrial transformation experience in biochemical extraction products, multi-component biochemical drugs, and synthetic peptide products, the technical level is leading domestically; In 2019, the group jointly launched internationally leading biopharmaceutical cutting-edge projects with senior research teams from the United States and Zhejiang University: The preparation of medicinal proteins using plant instantaneous expression systems, and the personalized treatment of tumors - neoantigen peptide project. All of these projects have made breakthrough progress and their technical level is internationally leading.